|Application ||WB, IHC-P, IF, E|
|Calculated MW||139096 Da|
|Antigen Region||751-780 aa|
|Other Names||Complement factor H, H factor 1, CFH, HF, HF1, HF2|
|Target/Specificity||This CFH antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 751-780 amino acids of human CFH.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||CFH Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Synonyms||HF, HF1, HF2|
|Function||Factor H functions as a cofactor in the inactivation of C3b by factor I and also increases the rate of dissociation of the C3bBb complex (C3 convertase) and the (C3b)NBB complex (C5 convertase) in the alternative complement pathway.|
|Tissue Location||Expressed by the liver and secreted in plasma.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene is a member of the Regulator of Complement Activation (RCA) gene cluster and encodes a protein with twenty short concensus repeat (SCR) domains. This protein is secreted into the bloodstream and has an essential role in the regulation of complement activation, restricting this innate defense mechanism to microbial infections. Mutations in this gene have been associated with hemolytic-uremic syndrome (HUS) and chronic hypocomplementemic nephropathy. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.
Dieterich, R., et al. Infect. Immun. 78(11):4467-4476(2010)
Sofat, R., et al. Atherosclerosis 213(1):184-190(2010)
Davila, S., et al. Nat. Genet. 42(9):772-776(2010)
Scambi, C., et al. PLoS ONE 5 (8), E12162 (2010) :
Bunkenborg, J., et al. Proteomics 4(2):454-465(2004)
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.